Drug intelligence / Profile preview

TV005

Development stage
Phase 1
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

TV005 is an investigational, single-dose **live-attenuated tetravalent dengue vaccine** developed by the National Institute of Allergy and Infectious Diseases. It is an admixture of attenuated recombinant dengue virus components representing dengue virus serotypes 1, 2, 3, and 4; compared with the related TV003 formulation, TV005 contains a ten-fold higher dose of its DENV-2 component to improve DENV-2 immunogenicity. The vaccine is intended to induce protective humoral and cellular immunity against all four dengue serotypes and has been evaluated in phase 1 and phase 2 studies, including controlled human infection studies showing protection against attenuated DENV-2 and DENV-3 challenge viruses. ([jci.org](https://www.jci.org/articles/view/173328))

Other names
TetraVax-DVTetraVax-DV TV005TetraVax-DV-TV005TetraVax-DV-TV-005TetraVax-DV-TV 005
02

Targets

CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))PRR (Pattern recognition receptors)

Beyond the preview

Go deeper on TV005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV005.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call